The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
Is there a link you can please share - apologies if you've already done that.
Bill.
In the here and now I don't agree, SOG. Its just not what I'm seeing from the CPF agreement - within the license agreement there are 'NO' (like zero) oncology indication on licensing provisions. Only non-oncology indication provisions.
'If' GSK want to on license, they are going to have to first sort something out with the CPF by way of a formal agreement. In that case, YES, I agree that being GSK will give them some helpful muscle in those discussions. But, the black and white of the agreement means they are going to have to get the CPF on board before being able to do any oncology indication on licensing.
Bill.
No worries, Heckler - looks like our two replies crossed at the same time.
Bill.
I think you are missing my point, Heckler.
Yes, with GSK assuming ownership of Sierra, they effectively assume the role of the license holder as set out in the agreement with the CPF.
What I was doing was responding to Thoth2's comment about licensing on SRA737 to a totally ***different*** party - in that case Zentalis. From what I can tell the agreement with the CPF doesn't give the freedom to do that. Thus if GSK want to go this route, they are going to have to agree something with the CPF. The agreement with the CPF only allows on licensing for non-oncology indications to a different/new party.
Bill.
Bill.
I think there is a need to be a bit careful with assumptions as to whether GSK can on-license SRA737.
I went right the way through the Sierra/CPF agreement and the only allowance for on-licensing I could find was for non-oncology indications. For oncology, the licence is given to Sierra exclusively without any options I could see for on licensing/sub licensing.
So, if GSK does want to on-license in some way, to my eyes it looks like GSK will have to approach the CPF and work out an updated/new agreement of some kind to facilitate that transaction.
Bill.
I’d expect it to close within 24 hours.
I saw that announcement. My read was that they were going to give this some focus with a more philanthropic approach, considering these diseases so heavily affect the developing world. I think this is 'in addition' to their other programs and aspirations (like oncology) and not instead of.
To be frank, I've got some doubts as to where GSK will go with SRA737 (though I am ultimately hopeful for a good outcome), but I certainly didn't read that piece on Friday and get even the slightest message that it would negatively affect SRA737.
Bill.
I think there are a few balls int he air, driving the GSK share price. The Haleon demerger (probably the single biggest factor), recent good data on a vaccine, approval of Priorix, Affinivax and Sierra. They seem to be enjoying a general run of positive news.
Bill
Thank you, WiP.
Bill
Good morning, WiP. Hope you had a good weekend.
How and when do you expect GSK to let us and the world know they are progressing SRA737?
Thanks,
Bill
I hope so. Hovering with my finger over the buy button for another 5,000-10,000 shares.
Bill.
Hello Elcap,
I believe it’s the end of this month. An, the next GSK reporting point + pipeline update is the end of July,
Bill
I am in complete agreement ndr50.
Its a nice idea but I don't see it happening at the moment.
I'm, sure the CTA announcement will come. To be precise, "mid-2022" to use Sareum's own words is the very end of June, very start of July. I take that to mean we are looking at plus or minus that by some amount. So, nobody should be falling off there chairs if this happens in July. Anyone invested just needs to tolerate lower trade volumes and some share price drift in the meantime.
I do agree with Lazarus, that there should be more news releases during H2 of this year, than there has been in H1. And, I think that the next year will be the making, or not, of Sareum.
Bill.
No need to apologise, WiP
I’ll just say I think quite a few have been misreading my intentions here.
Have a good night.
Bill
* I didn’t see your post you referred to.
Thanks, WiP
Regret, I’ve been doing my best doing a deeper dive on Sareum. At times I’ve not been able to read every post. I did see the one you referred to. As you’ve raise it, I’ll go back and take a look.
As for the “ wouldn’t put it past them to sit on assets to deny competitors access”. No, I didn’t say that. If you look it’s was earlier post from Star786.
I was actually throwing my hands up in the air, saying and people are accusing me of being negative, what about that….
Thanks,
Bill
I never doubted the acquisition due diligence covering this. What I'd been looking for was some explicit SRA737 recognition by GSK.
As you say Heckler, its comforting.
Bill
I really, really hope you are right Celtic. And, the paragraph in that press release gives some definite comfort.
Bill
wouldn't put it past them to sit on the assets to deny competitors access
And people are accusing me of being negative....
Bill